Head and Neck TumorsHead and Neck TumorsОпухоли головы и шеи2222-14682411-4634Publishing House ABV Press52210.17650/2222-1468-2020-10-2-10-21DIAGNOSIS AND TREATMENT OF HEAD AND NECK TUMORSДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ ГОЛОВЫ И ШЕИInfluence of the results of international studies on the choice of treatment tactics for unresectable forms of squamous cell carcinoma of the head and neckВлияние результатов международных исследований на выбор лечебной тактики при нерезектабельных формах плоскоклеточного рака головы и шеиhttps://orcid.org/0000-0003-4879-2687BolotinaL. V.БолотинаЛ. В.
Russian Federation

3 2 nd Botkinsky Dr., Moscow 125284

Лариса Владимировна Болотина  

125284 Москва, 2-й Боткинский пр-д, 3

lbolotina@yandex.ruhttps://orcid.org/0000-0002-3371-7548DeshkinaT. I.ДешкинаТ. И.
Russian Federation

3 2 nd Botkinsky Dr., Moscow 125284

125284 Москва, 2-й Боткинский пр-д, 3

https://orcid.org/0000-0003-0092-0459KornietskayaA. L.КорниецкаяА. Л.
Russian Federation

3 2 nd Botkinsky Dr., Moscow 125284

125284 Москва, 2-й Боткинский пр-д, 3

https://orcid.org/0000-0002-0681-8976KravtsovS. A.КравцовС. А.
Russian Federation

17/1 Baumanskaya St., Moscow 105005

105005 Москва, ул. Бауманская, 17/1

https://orcid.org/0000-0002-2061-0522UstinovaT. V.УстиноваТ. В.
Russian Federation

3 2 nd Botkinsky Dr., Moscow 125284

125284 Москва, 2-й Боткинский пр-д, 3

https://orcid.org/0000-0001-7912-8055PaychadzeA. A.ПайчадзеА. А.
Russian Federation

3 2 nd Botkinsky Dr., Moscow 125284

125284 Москва, 2-й Боткинский пр-д, 3

https://orcid.org/0000-0001-8784-8415KaprinA. D.КапринА. Д.
Russian Federation

3 2 nd Botkinsky Dr., Moscow 125284

125284 Москва, 2-й Боткинский пр-д, 3

FedenkoА. А.ФеденкоА. А.
Russian Federation

3 2 nd Botkinsky Dr., Moscow 125284

125284 Москва, 2-й Боткинский пр-д, 3

P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiology Center, Ministry of Health of RussiaМосковский научно-исследовательский онкологический институт им. П.А. Герцена – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава РоссииCity Clinical Hospital No. 1, Moscow Healthcare DepartmentГБУЗ «Городская клиническая онкологическая больница № 1 Департамента здравоохранения г. Москвы»2407202010210212307202023072020Copyright ©; 2020, Bolotina L.V., Deshkina T.I., Kornietskaya A.L., Kravtsov S.A., Ustinova T.V., Paychadze A.A., Kaprin A.D., Fedenko А.А.Copyright ©; 2020, Болотина Л.В., Дешкина Т.И., Корниецкая А.Л., Кравцов С.А., Устинова Т.В., Пайчадзе А.А., Каприн А.Д., Феденко А.А.2020Bolotina L.V., Deshkina T.I., Kornietskaya A.L., Kravtsov S.A., Ustinova T.V., Paychadze A.A., Kaprin A.D., Fedenko А.А.Болотина Л.В., Дешкина Т.И., Корниецкая А.Л., Кравцов С.А., Устинова Т.В., Пайчадзе А.А., Каприн А.Д., Феденко А.А.https://creativecommons.org/licenses/by/4.0https://ogsh.abvpress.ru/jour/article/view/522

The results of the clinical studies have a direct impact on clinical practice. The main criteria for the effectiveness of treatment method are increasing the overall life expectancy and improving its quality. In the treatment of common forms of squamous cell carcinoma of the head and neck, induction chemotherapy can be used, including platinum drugs, preferably in combination with cetuximab. Next immuno-oncological drugs should be prescribed. In the future, in the 1st line of therapy, it is possible to replace cetuximab with pembrolizumab or monotherapy with pembrolizumab, which allows to increase the effectiveness of treatment and reduce its toxicity. The article presents 3 clinical observations that demonstrate the possibility of integration the results of clinical research in practice.

Результаты исследований оказывают прямое влияние на клиническую практику. Основными критериями эффективности тех или иных методов лечения остаются увеличение общей продолжительности жизни и улучшение ее качества. При лечении распространенных форм плоскоклеточного рака органов головы и шеи может использоваться индукционная химиотерапия, в том числе препаратами платины предпочтительно в комбинации с цетуксимабом. В дальнейшем должны назначаться иммуноонкологические препараты. В перспективе в 1-й линии терапии возможна замена цетуксимаба на пембролизумаб или монотерапия пембролизумабом, что позволяет повысить эффективность лечения и снизить его токсичность. В статье представлены 3 клинических наблюдения, демонстрирующие возможность внедрения результатов клинических исследований в практику.

squamous cell carcinoma of the head and neckplatinum-based chemotherapyimmuno-oncological drugsnivolumabpembrolizumab1st line drug therapyPD-L1 expressionплоскоклеточный рак головы и шеиплатиносодержащая химиотерапияиммуноонкологические препаратыниволумабпембролизумаблекарственная терапия 1-й линииэкспрессия PD-L11. Beishon M. Too high or too low? ESMO’s clinical benefit scale fuels debate over approval thresholds. CancerWorld 2018;(81):5–11.Beishon M. Too high or too low? ESMO’s clinical benefit scale fuels debate over approval thresholds. CancerWorld 2018;(81):5–11.2. Breast Cancer. NCCN Clinical Practice Guidelines in Oncology, Version 3.2019. P. 68.Breast Cancer. NCCN Clinical Practice Guidelines in Oncology, Version 3.2019. P. 68.3. Ravaud A., Motzer R.J., Pandha H.S. et al. Adjuvant sunitinib in high risk renalcell carcinoma after nephrectomy. N Engl J Med 2016;375(23):417–27. DOI: 10.1056/NEJMoa1611406.Ravaud A., Motzer R.J., Pandha H.S. et al. Adjuvant sunitinib in high risk renalcell carcinoma after nephrectomy. N Engl J Med 2016;375(23):417–27. DOI: 10.1056/NEJMoa1611406.4. Baselga J., Campone M., Piccart M. et al. Everolimus in postmenopausal hormonereceptor-positive advanced breast cancer. N Engl J Med 2012;366(6):520–9. DOI: 10.1056/NEJMoa1109653.Baselga J., Campone M., Piccart M. et al. Everolimus in postmenopausal hormonereceptor-positive advanced breast cancer. N Engl J Med 2012;366(6):520–9. DOI: 10.1056/NEJMoa1109653.5. Ghi M.G., Paccagnella A., Ferrari D. et al. Concomitant chemoradiation (CRT) or cetuximab/RT(CET/RT) versus induction docetaxel/cisplatin/5-fluorouracil (TPF) followed by CRT or CET/RT in patients with locally advanced squamous cell carcinoma of head and neck (LASCCHN). A randomized phase III factorial study (NCT01086826). J Clin Oncol 2014;32(15 Suppl):6004. DOI: 10.1200/jco.2014.32.15_suppl.6004.Ghi M.G., Paccagnella A., Ferrari D. et al. Concomitant chemoradiation (CRT) or cetuximab/RT(CET/RT) versus induction docetaxel/cisplatin/5-fluorouracil (TPF) followed by CRT or CET/RT in patients with locally advanced squamous cell carcinoma of head and neck (LASCCHN). A randomized phase III factorial study (NCT01086826). J Clin Oncol 2014;32(15 Suppl):6004. DOI: 10.1200/jco.2014.32.15_suppl.6004.6. Grose W.E., Lehane D.E., Dixon D.O. et al. Comparison of methotrexate and cisplatin for patients with advanced squamous cell carcinoma of the head and neck region: a southwest oncology group study. Cancer Treat Rep 1985;69(6):577–81.Grose W.E., Lehane D.E., Dixon D.O. et al. Comparison of methotrexate and cisplatin for patients with advanced squamous cell carcinoma of the head and neck region: a southwest oncology group study. Cancer Treat Rep 1985;69(6):577–81.7. Williams S.D., Velez-García E., Essessee I. et al. Chemotherapy for head and neck cancer: comparison of cisplatin + vinblastine + bleomycin versus methotrexate. Cancer 1986;57(1):18–23.Williams S.D., Velez-García E., Essessee I. et al. Chemotherapy for head and neck cancer: comparison of cisplatin + vinblastine + bleomycin versus methotrexate. Cancer 1986;57(1):18–23.8. Forastiere A., Metch B., Schuller D.E. et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck. Southwest Oncology Group Study. J Clin Oncol 1992;10(8):1245–51. DOI: 10.1200/JCO.1992.10.8.1245.Forastiere A., Metch B., Schuller D.E. et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck. Southwest Oncology Group Study. J Clin Oncol 1992;10(8):1245–51. DOI: 10.1200/JCO.1992.10.8.1245.9. Jacobs C., Lyman G., Velez-García E. et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10(2):257–63. DOI: 10.1200/JCO.1992.10.2.257.Jacobs C., Lyman G., Velez-García E. et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10(2):257–63. DOI: 10.1200/JCO.1992.10.2.257.10. Gibson M.K., Li Y., Murphy B. et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23(15):3562–7. DOI: 10.1200/JCO.2005.01.057.Gibson M.K., Li Y., Murphy B. et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23(15):3562–7. DOI: 10.1200/JCO.2005.01.057.11. Fan Z., Baselga J., Masui H., Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993;53(19):4637–42.Fan Z., Baselga J., Masui H., Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993;53(19):4637–42.12. Vermorken J.B., Mesía R., Rivera F. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116–27. DOI: 10.1056/NEJMoa0802656.Vermorken J.B., Mesía R., Rivera F. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116–27. DOI: 10.1056/NEJMoa0802656.13. Vermorken J.B., Psyrri A., Mesía R. et al. Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial. Ann Oncol 2014;25(4):801–7. DOI: 10.1093/annonc/mdt574.Vermorken J.B., Psyrri A., Mesía R. et al. Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial. Ann Oncol 2014;25(4):801–7. DOI: 10.1093/annonc/mdt574.14. Fullerton Z.H., Butler S.S., Mahal B.A. et al. Short-term mortality risks among patients with oropharynx cancer by human papillomavirus status. Cancer 2020;126(7): 1424–33. DOI: 10.1002/cncr.32652.Fullerton Z.H., Butler S.S., Mahal B.A. et al. Short-term mortality risks among patients with oropharynx cancer by human papillomavirus status. Cancer 2020;126(7): 1424–33. DOI: 10.1002/cncr.32652.15. Guigay J., Mesia R., Bourhis J. et al. TPExtreme randomized trial: TPEx versus EXTREME regimen in 1 line recurrent/ metastatic head and neck squamous cell carcinoma. J Clin Oncol 2015;33(15 Suppl): TPS6087. DOI: 10.1200/jco.2015.33.15_suppl.tps6087.Guigay J., Mesia R., Bourhis J. et al. TPExtreme randomized trial: TPEx versus EXTREME regimen in 1 line recurrent/ metastatic head and neck squamous cell carcinoma. J Clin Oncol 2015;33(15 Suppl): TPS6087. DOI: 10.1200/jco.2015.33.15_suppl.tps6087.16. Ferris R.L., Blumenschein G. Jr, Fayettee J. et al. Nivolumab for recurrent squamous cell carcinoma of the head and neck. N Engl J Med 2016;375(19):1856–67. DOI: 10.1056/NEJMoa1602252.Ferris R.L., Blumenschein G. Jr, Fayettee J. et al. Nivolumab for recurrent squamous cell carcinoma of the head and neck. N Engl J Med 2016;375(19):1856–67. DOI: 10.1056/NEJMoa1602252.17. Cohen E.E.W., Harrington K.J., Tourneau C.L. et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 2019;393(10167):156–67. DOI: 10.1016/S0140-6736(18)31999-8.Cohen E.E.W., Harrington K.J., Tourneau C.L. et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 2019;393(10167):156–67. DOI: 10.1016/S0140-6736(18)31999-8.18. Rischin D., Harrington K.J., Greil R. et al. Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). J Clin Oncol 2019;37(suppl):6000.Rischin D., Harrington K.J., Greil R. et al. Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). J Clin Oncol 2019;37(suppl):6000.